Navigation Links
Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation
Date:7/22/2014

WASHINGTON, July 22, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced that Edwards' Chairman and CEO Michael A. Mussallem today served as an expert panelist at the invitation of the United States Energy and Commerce Committee's Subcommittee on Health to discuss medical device innovation at its hearing, "21st Century Cures: Examining Barriers to Ongoing Evidence Development and Communication."

"Edwards has five decades of experience in developing and delivering new therapies to American patients, and we are concerned about the alarming and documented decline in U.S. medical innovation," said Mussallem.  "We identified areas of improvement that we believe can support a balanced ecosystem, which welcomes innovations to enable patients to live longer, healthier lives."

Mussallem noted the constructive and collaborative relationship with the Food and Drug Administration and the Centers for Medicare & Medicaid Services and identified three primary areas of improvement to promote America's leadership in medical device development, and ensure delivery of new treatments to patients around the world:

  • Evidence development mechanisms can be improved to reduce costs and delays.
  • Economic incentives need to be aligned with promoting innovation.
  • FDA's vision to improve the regulatory process must be accelerated.  

Mussallem drew on Edwards' experience with the SAPIEN transcatheter aortic heart valves to discuss the regulatory and reimbursement challenges and opportunities in the U.S.  His full written comments can be read at

SOURCE Edwards Lifesciences Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
2. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
3. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
4. Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
5. Edwards Lifesciences Chief Medical Officer to Keynote the Inaugural MedTech Cardio 2012 Conference at the MD&M Minneapolis Exposition and Conference
6. Updated: Harwood Feffer LLP Announces Investigation of Edwards Lifesciences Corporation
7. Acquisitions, Conference Participations, Court Rulings, and Product Deliveries - Research Report on Zoetis, Aegerion Pharmaceuticals, Edwards, Community Health Systems, and Air Methods
8. New Appointments, and Share Price Movements - Research Report on Humana, Illumina, Edwards Lifesciences, Aegerion Pharmaceuticals, and CytRx
9. RxAlly Member Pharmacies Invited To Become The Preferred Network For Smart Insurance Company Holdings, Inc.
10. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
11. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... (Nasdaq: THOR ), a world leader in device-based ... hearts, today announced that it will report its operating results ... 1. The company will hold a conference call ... all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30 ...
... 2011 At the 5 ... in Barcelona, Spain (20-22 October 2011),   Merz Pharmaceuticals ... efficacy and safety of   XEOMIN ® ... Dystonia is a particularly debilitating condition ...
Cached Medicine Technology:Thoratec Schedules Third Quarter Conference Call, Webcast 2Merz research Shows Long-term Benefits for Patients With Dystonia 2Merz research Shows Long-term Benefits for Patients With Dystonia 3Merz research Shows Long-term Benefits for Patients With Dystonia 4
(Date:1/22/2015)... 2015 The U.S. Pharmacopeial Convention is ... of Clinical Pharmacy Services at North Carolina State’s College ... the 2015 Beal Award for Distinguished Volunteer Service—the organization’s ... on the contributions of volunteer experts to direct its ...
(Date:1/22/2015)... Nashville, TN (PRWEB) January 22, 2015 Gabe’s Chemo ... Chemo Duck App, the first app ever created for kids with ... all Apple phones and devices, is filled with enjoyable games to ... life and treatments. The free app helps to keep kids entertained, ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... disease requiring creative solutions for diagnosis, quality of life ... San Antonio Breast Cancer Symposium explore these areas. ... Cancer , Abstract #65, Sarah Marshall, M.A. , Although ... breast cancer, they appear to mitigate the mortality risk ...
... PartsSource, the nation,s leading,supplier of replacement medical repair parts for ... in Ohio by the Case Western Reserve,University Weatherhead ... placed 14th on this year,s list with a growth rate ... eligible. , "The Weatherhead ...
... WASHINGTON, Dec. 12 [The Washington Post ... and Drug Administration and the White House are considering easing ... certain fish. Scientists at the Environmental Protection Agency reportedly ... The move is one of several "midnight" rules and policy ...
... treatment decisions, study shows , , FRIDAY, Dec. 12 ... the risk of their breast cancer returning after ... get chemotherapy more difficult, a new study concludes. ... bar chart, based on a standard risk-assessment tool, ...
... Care Policy and Legislative Background Assures Strong Leadership for ... , WASHINGTON, Dec. 12 ... nation,s largest cancer treatment and research networks representing approximately ... of former Senator Tom Daschle to lead his newly ...
... report from the Institute of Medicine, THE U.S. COMMITMENT ... why a commitment to global health is an important ... the current economic situation. The report describes areas ... incoming administration should strive to meet, and makes specific ...
Cached Medicine News:Health News:Patient management: Quality of life and beyond 2Health News:Risk Info for Breast Cancer Patients Too Confusing 2Health News:US Oncology Applauds Senator Daschle's Appointment as Director of President-Elect Obama's New White House Office of Health Reform 2
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Resolve Immersion Oil is a clear, ... throughout most of the UV-VIS spectrum. ... and high viscosity, is non-drying and ... of 1.5150. Resolve contains no PCBs, ...
Medicine Products: